GTH - Genetron Holdings Limited

NasdaqGM - NasdaqGM Delayed price. Currency in USD

Genetron Holdings Limited

Building 11
1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District
Beijing 102206
86 10 5090 7500

IndustryDiagnostics & Research
Full-time employees993

Key executives

NameTitlePayExercisedYear born
Mr. Sizhen WangCo-Founder, CEO & ChairmanN/AN/A1977
Dr. Wei-Wu He Ph.D.Co-Founder & Chairman EmeritusN/AN/A1965
Dr. Hai YanCo-Founder, Chief Scientific Officer & DirectorN/AN/A1968
Mr. Ce XuChief Financial OfficerN/AN/A1982
Ms. Victoria LeiChief Operating OfficerN/AN/AN/A
Dr. Yuchen Jiao M.D., Ph.D.Chief Technology OfficerN/AN/A1978
Mr. Yong LiangChief HR OfficerN/AN/A1974
Dr. Yun-Fu Hu Ph.D.Chief Medical OfficerN/AN/A1963
Ms. Lily LiuChief Commercial OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.

Corporate governance

Genetron Holdings Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.